Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients
Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients
复制标题
基于 13 基因特征的联合治疗敏感性指数可预测 IDH 野生型和 MGMT 启动子非甲基化胶质母细胞瘤患者的预后
DOI：
10.7150/jca.30614
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Li, Xuejun
中科院分区：
文献类型：
--
作者：
Ye, Ningrong;Jiang, Nian;Li, Xuejun
胶质母细胞瘤是一种预后较差的致死性肿瘤。然而，预测预后的方法还需要进一步探索。因此，我们开发了一种可用于预测GBM患者预后的评估系统。对已发表的肿瘤基因组图谱(TCGA)、基因表达总览(GEO)和中国人脑胶质瘤基因组图谱(CGGA)中的基因表达数据进行分析。采用实时荧光定量聚合酶链式反应技术，对178例湘雅GBM患者的标志性基因和分子突变进行了验证。基因集丰富分析(GSEA)用于功能注释。因此，我们建立了13个基因的标记，命名为联合治疗敏感性指数(CTSI)。根据一个分界点，我们将患者分为高风险组和低风险组。经Kaplan-Meier分析和多因素Cox回归分析，高危组患者总体生存时间明显短于低危组(P<0.05)。
Glioblastoma (GBM) is one of the lethal tumors with poor prognosis. However, prognostic prediction approaches need to be further explored. Therefore, we developed an evaluation system that could be used for prognostic prediction of GBM patients. Published mRNA expression datasets from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Chinese Glioma Genome Atlas (CGGA) were analyzed. Quantitative Realtime-PCR of signature genes and molecular aberrations of 178 Xiangya GBM patients were used for confirmation. Gene set enrichment analysis (GSEA) was performed for functional annotation. As a result, we established a 13-gene signature which named Combined Therapy Sensitivity Index (CTSI). Based on a cutoff point, we divided patients into high-risk group and low-risk group. Based on Kaplan-Meier analysis and multivariate Cox regression analysis, we found that patients in the high-risk group had a shorter overall survival time than patients in the low-risk group (p